Circulating tumor cells are an indicator for the administration of adjuvant transarterial chemoembolization in hepatocellular carcinoma: A single-center, retrospective, propensity-matched study
Circulating tumor cells are an indicator for the administration of adjuvant transarterial chemoembolization in hepatocellular carcinoma: A single-center, retrospective, propensity-matched study
复制标题
循环肿瘤细胞是肝细胞癌辅助经动脉化疗栓塞治疗的指标：一项单中心、回顾性、倾向匹配研究
DOI：
10.1002/ctm2.137
复制
发表时间：
2020-07-23
影响因子：
10.6
通讯作者：
Yang, Xin-Rong
中科院分区：
文献类型：
--
作者：
Wang, Peng-Xiang;Sun, Yun-Fan;Yang, Xin-Rong
背景：肝细胞癌（HCC）术后肿瘤复发率高，导致预后不良。在此，我们研究了循环肿瘤细胞（CTC）状态是否可以预测辅助性经导管动脉化疗栓塞（TACE）在HCC患者中的获益。方法回顾性分析344例HCC患者术前CTC分析。比较了接受和未接受辅助TACE的患者的临床结局，包括复发和生存率。对根据CTC状态分层的患者进行类似比较（CTC阴性[CTC = 0]，n = 123; CTC阳性[CTC >= 1]，n = 221）。采用倾向评分匹配（PSM）策略来抵消两组之间的差异。结果TACE组和对照组的总生存期（OS）和复发时间（TTR）无显著性差异（P > 0.05）。在CTC阳性患者中，PSM产生了64个患者对，辅助TACE患者的临床结局明显更好（OS：未达到vs 36.4个月，P <0.001; TTR：45.8 vs 9.8个月，P <0.001）。辅助TACE显著降低了早期复发（
Background High rates of postoperative tumor recurrence contribute to poor outcome in hepatocellular carcinoma (HCC). Here, we investigated whether circulating tumor cells (CTCs) status can predict the benefit of adjuvant transcatheter arterial chemoembolization (TACE) in patients with HCC. Methods The retrospective study enrolled 344 HCC patients with preoperative CTCs analysis. Clinical outcomes including recurrence and survival were compared between those who received and who did not receive adjuvant TACE. Similar comparisons were made for patients stratified according to CTC status (CTC-negative [CTC = 0], n = 123; CTC-positive [CTC >= 1], n = 221). Propensity score matching (PSM) strategy was adopted to offset differences between two groups. Results In the study cohort as a whole or in CTC-negative cohort, there were no observable differences in overall survival (OS) or time to recurrence (TTR) between TACE and control group (P > .05). In CTC-positive patients, PSM generated 64 patient pairs, and patients with adjuvant TACE had significantly better clinical outcomes (OS: not reached vs 36.4 months,P < .001; TTR: 45.8 vs 9.8 months,P < .001). Adjuvant TACE significantly reduced early recurrence (